Meet AZN management: ASCO 2020
Virtual breakout 3: Lynparza

Susan Galbraith, Greg Rossi
IR moderator: Nick Stone

1 June 2020
Webinar is being recorded
Forward-looking statements disclaimer

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK’s exit from the EU; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
**Lynparza: ovarian cancer**

The most comprehensive PARPi\(^1\) development programme in ovarian cancer

---

**Study 19: 3L+**

SOLO-2: 2L maintenance

PAOLA-1: 1L (HRD+ve\(^2\))

ASCO 2020: continued advancement of science supporting *Lynparza*

Phase III SOLO2
- Final OS for maintenance treatment in BRCA\(^3\)-mutated PSR\(^4\) OC\(^5\)

Other
- Phase IIIb OPINION IA\(^6\): maintenance of non-germline BRCA1/2-mutated PSR OC
- Phase III: *Lynparza* or the combination of cediranib and *Lynparza* to standard platinum-based CTx\(^7\) in recurrent platinum-sensitive OC
- Phase II LIGHT: PSR ovarian cancer by BRCA mutation and HRD status

---

1. Poly ADP ribose polymerase (PARP) inhibitor.
2. Homologous recombination deficiency (HRD) positive, including tBRCAm.
3. Breast cancer susceptibility gene 1/2 mutation
4. Platinum-sensitive relapsed
5. Ovarian cancer
6. Interim analysis
7. Chemotherapy.

Source: Study 19, abstract SS01, ASCO 2016; and SOLO-2, 2 - Late Breaking Abstract, SGO 2017.
Lynparza: SOLO2 final OS
Maintenance treatment for PSR OC patients with gBRCA positive tumours

PFS: 63% maturity with a median follow up ~22 months

SOLO2: median OS improved by 12.9 months with maintenance Lynparza over placebo (p-value: 0.0537)

1. Time to first subsequent therapy.

2. Prespecified adjusted OS analysis (RPSFT model, re-censored): to adjust for subsequent PARP inhibitor therapy in placebo group. The RPSFT model (re-censored) adjusts for the 38% of placebo patients who received subsequent PARP inhibitor therapy. RPSFT: rank preserving structural failure time model. Source: abstract 6002, ASCO 2020.
**Lynparza: PAOLA-1**

1L maintenance treatment with bevacizumab

### PAOLA-1: 1L ovarian cancer

- **Maintenance therapy**
  - 1L (complete response; partial response; or non-evidence of disease)
  - Randomisation (2:1)
  - **Lynparza (two years) + bevacizumab**
  - Placebo (two years) + bevacizumab

- Progression-free survival (PFS1)

- Follow up for second progression (PFS2) or death

- Overall survival

### PAOLA-1: biomarker subgroups

**~1 in 2**

- women with advanced OC are HRD+ve

- HRD-ve³;
  - n=277; 34%

- HRD+ve;
  - n=387; 48%

- HRD status unknown;
  - n=142; 18%

### Approved

1L maintenance treatment in the US with bevacizumab for HRD+ve advanced OC

PAOLA-1 demonstrated the predictive value of HRD testing

>37 months mPFS for patients treated with *Lynparza* + bevacizumab

---

1. Bevacizumab: 15mg/kg, every 3 weeks for a total of 15 months, including when administered with chemotherapy
2. Secondary endpoints.
3. HRD negative.


Source: ESMO 2019.
Lynparza: PAOLA-1 and PRIMA

Maintenance treatment essential; HRD testing critical to obtain longest mPFS

Indirect treatment comparison of PAOLA-1 and PRIMA PFS: HRD+ve

After adjustment, in HRD+ve patients, the benefit was greatest with Lynparza + bevacizumab combination therapy

1. Niraparib (by Tesaro/GSK); https://clinicaltrials.gov/ct2/show/NCT02655016.
2. Adjusted analysis, formal matching analysis of the PAOLA-1 patients’ characteristics to the PRIMA patients’ characteristics, in the absence of randomized controlled trial. Source: poster 223, ASCO 2020.

Indirect treatment comparison of PAOLA-1 and PRIMA PFS: HRD-ve

After adjustment, in HRD-ve patients, the benefit was greatest with either of the bevacizumab containing regimens (bevacizumab alone or Lynparza + bevacizumab)

**Lynparza: ovarian cancer**

**Continued global expansion**

**+69%**
Product sales growth Q1 2020

**$397m**
Product sales Q1 2020

<table>
<thead>
<tr>
<th>Tumour/setting</th>
<th>US</th>
<th>Europe</th>
<th>Japan</th>
<th>China</th>
<th>Country approvals</th>
<th>Countries reimbursed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovarian</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>73</td>
<td>&gt;40</td>
</tr>
<tr>
<td>Breast</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>⚫</td>
<td>64</td>
<td>8</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>✔</td>
<td>⚫</td>
<td>✔</td>
<td>⚫</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Prostate</td>
<td>✔</td>
<td>⚫</td>
<td>⚫</td>
<td>⚫</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country</th>
<th>Approvals</th>
<th>Reimbursed</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>Under regulatory review</td>
<td></td>
</tr>
</tbody>
</table>

**Established Row**

**Emerging Markets**

**Europe**

Product sales by region

**Patient focus: health economic analysis in Italy to demonstrate the added benefit that Lynparza offers to patients**

AstraZeneca showed the cost-effectiveness of a preventive testing strategy in relatives of patients with BRCA mutated ovarian cancer versus a no testing strategy. The evaluation showed how it is cost-effective to include BRCA tests for patients and family of those with a family history of breast/ovarian cancer.

Product sales at actual exchange rates; change at constant exchange rate. Source: AstraZeneca data on file.
**Lynparza:** the only PARPi to improve overall survival in prostate cancer patients

PROfound, cohort A

1. Lynparza vs. enzalutamide or abiraterone in a biomarker-based subset BRCA1/2 or ATM-mutations.
2. Ataxia telangiectasia mutated.

Questions & Answers

To ask a question

**Webinar**

Click ‘Raise Hand’ (preferred):

or type your question into the Q&A box (alternative)

**Phone**

*6 - Toggle mute/unmute
*9 - Raise hand
Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com